NBP — NovaBridge Biosciences
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1778016 ·
Last close
$1.47
Market Cap
$170.00M
52W High
$3.14
52W Low
$1.46
ADV30
761,116
Next earnings
2026-06-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -72,900,000 | -30,787,000 | 260,522,000 | 210,632,000 | 29,581,000 |
| Sep 2025 | 0 | — | -8,989,000 | -6,828,000 | 277,410,000 | 228,064,000 | 18,495,000 |
| Jun 2025 | 0 | — | -7,114,000 | -5,504,000 | 206,708,000 | 165,404,000 | 9,975,000 |
| Mar 2025 | 0 | — | -5,266,000 | -3,150,000 | 208,941,000 | 53,597,000 | 10,600,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,284,000
Investing CF
$-81,764,000
Financing CF
$57,725,000
CapEx
$-39,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.37
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,332,308,000
Inventory
—
Receivables
$1,793,000
ST Investments
$210,000
EBIT TTM
$-94,269,000
Pretax Income TTM
$-88,340,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -94,269,000 | -46,269,000 | 260,522,000 | 29,581,000 | — | -20,597,000 |
| Dec 2024 | 0 | -51,426,000 | -22,230,000 | 212,680,000 | 11,520,000 | — | -52,669,000 |
| Dec 2023 | 632,000 | -48,976,000 | -207,729,000 | 368,922,000 | 126,338,000 | — | -72,697,000 |
| Dec 2022 | -1,551,000 | -53,078,000 | -371,053,000 | 590,446,132 | 168,678,417 | — | -49,582,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.06
Max Pain — expiry 2026-06-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.51 · call volume: 1 · put volume: 40
Expected Move to 2026-06-18:
±$1.18
(77.81%) —
implied range
$0.33 –
$2.68
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OKUR | OnKure Therapeutics, Inc. | $169.66M | $4.20 | — |
| SPRO | Spero Therapeutics, Inc. | $168.49M | $2.91 | — |
| KRRO | Korro Bio, Inc. | $168.17M | $11.66 | — |
| GALT | GALECTIN THERAPEUTICS INC | $172.55M | $2.62 | — |
| NRXP | NRX Pharmaceuticals, Inc. | $174.63M | $4.08 | — |
News headlines (Yahoo Finance, 1h cache)
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
2026-06-16 11:00 · Yahoo
Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth
2026-05-28 11:50 · Yahoo
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-28 11:00 · Yahoo
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
2026-05-12 11:00 · Yahoo
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
2026-04-22 11:00 · Yahoo
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
2026-04-07 20:50 · Yahoo
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
2026-03-16 11:00 · Yahoo
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
2026-03-09 11:00 · Yahoo
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
2026-03-03 14:05 · Yahoo
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
2026-03-02 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.